Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-17
    E.g., 2018-11-17

Articles

173760 items
8:01 AM, Nov 16, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Bayer's Stivarga first to enter adaptive brain cancer trial

Bayer AG (Xetra:BAYN) and the Global Coalition for Adaptive Research (GCAR) said Stivarga regorafenib will be the first therapy to enter the adaptive Phase II/III GBM AGILE trial, which has been designed to more rapidly...
8:01 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

MEI Pharma outlicenses PI3K inhibitor to Kyowa in Japan, BeiGene in China

MEI Pharma Inc. (NASDAQ:MEIP) granted Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) exclusive rights in Japan to develop and commercialize ME-401, initially for relapsed or refractory follicular lymphoma. ME-401 is a phosphoinositide 3-kinase δ (PI3Kδ) inhibitor....
8:01 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Theravance sells Vibativ to Cumberland

Theravance Biopharma Inc. (NASDAQ:TBPH) sold antibiotic Vibativ telavancin to Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) for $25 million. Theravance is eligible for tiered royalties of up to 20%. Theravance recorded $5.4 million in Vibativ sales in 2Q18....
8:00 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Covis gains full rights to ciclesonide drugs from AZ

Covis Pharma S.a.r.l. (Zug, Sweden) will acquire ex-U.S. rights to Alvesco, Omnaris and Zetonna from AstraZeneca plc (LSE:AZN; NYSE:AZN) for $350 million. Covis acquired U.S. rights to the drugs, all of which contain the active...
8:00 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Celgene pays Dragonfly $50M to expand NK cell immunotherapy deal

Celgene Corp. (NASDAQ:CELG) expanded its deal with Dragonfly Therapeutics Inc. (Waltham, Mass.), doubling the number of trispecific NK cell engager cancer compounds that Celgene may in-license. Under the expansion, Celgene will pay Dragonfly $50 million up...
7:59 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Dana-Farber, Deerfield launching Center for Protein Degradation

Dana-Farber Cancer Institute and Deerfield Management partnered to create the Center for Protein Degradation, which will be led by Dana-Farber investigators and Harvard Medical School professors Nathanael Gray and Eric Fischer. Located at Dana-Farber, the...
7:59 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

LogicBio, CMRI partner to develop next-generation viral vectors

Gene therapy company LogicBio Therapeutics Inc. (NASDAQ:LOGC) and Children's Medical Research Institute (CMRI) (Westmead, Australia) partnered to develop next generation adeno-associated virus (AAV) capsids through their newly launched AAV Development Program. LogicBio scientific co-founder Leszek Lisowski...
7:59 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) in a Nov. 15 deal that highlights how far Arena’s come since it shifted its focus...
7:59 AM, Nov 16, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

At $500M, Moderna files to raise record IPO

mRNA company Moderna Therapeutics Inc. (Cambridge, Mass.) filed on Nov. 9 to raise $500 million in an IPO on NASDAQ, which would mark the largest IPO on the exchange for a development stage biotech. Flagship Pioneering...
7:58 AM, Nov 16, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Opko raises $92.5M in private placement

Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK) raised $92.5 million in a private placement on Nov. 8 through the sale of 26.5 million shares at $3.49. The price is a 10% discount to Opko's close of...

Pages